| Identification | Back Directory | [Name]
L-Phenylalaninamide, D-arginyl-2,6-dimethyl-L-tyrosyl-L-lysyl-, 2,2,2-trifluoroacetate (1:1) | [CAS]
1606994-55-1 | [Synonyms]
RX-31 TFA
SS-31 TFA)
MTP-131 (TFA)
Elamipretide TFA
Elamipretide TFA (MTP-131 TFA
ELAMIPRETIDE TFA (MTP-131 TFA; RX-31 TFA; SS-31 TFA)
L-Phenylalaninamide, D-arginyl-2,6-dimethyl-L-tyrosyl-L-lysyl-, 2,2,2-trifluoroacetate (1:1) | [Molecular Formula]
C34H50F3N9O7 | [MDL Number]
MFCD31746869 | [MOL File]
1606994-55-1.mol | [Molecular Weight]
753.83 |
| Chemical Properties | Back Directory | [storage temp. ]
Store at -20°C | [form ]
Solid | [Water Solubility ]
Soluble in Water | [InChIKey]
WLZHRKGRZBGUJU-PMZDVTNTNA-N | [SMILES]
C(F)(F)(F)C(=O)O.[C@@H](NC(=O)[C@H](N)CCCNC(N)=N)(C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N)CC1C=CC=CC=1)CC1C(=CC(O)=CC=1C)C |&1:7,11,23,32,r| |
| Hazard Information | Back Directory | [Description]
Elamipretide TFA (MTP-131 TFA; RX-31 TFA; SS-31 TFA) is a cardiolipin peroxidase inhibitor and mitochondria-targeting peptide[1]. Cardiolipin peroxidase[1] | [Uses]
Elamipretide TFA (MTP-131 TFA; RX-31 TFA; SS-31 TFA) is the TFA salt form of Elamipretide (HY-P0125). Elamipretide TFA is a mitochondria-targeting peptide, which ameliorates myocardial infarction, improves the renal function and protects neurons form inflammatory and oxidative stress injury[1][2]. | [in vivo]
Elamipretide TFA (5 mg/kg, i.p., once daily for 3 days) exhibits neuroprotective effects, protects the hippocampus from mitochondrial dysfunction, and attenuates the oxidative stress and inflammatory response in Lipopolysaccharide (HY-D1056)-induced cognitive impairment in C57BL/6 mice model[1].
| Animal Model: | LPS-induced cognitive impairment in C57BL/6 mice model[1] | | Dosage: | 5 mg/kg | | Administration: | i.p., once daily for 3 days | | Result: | Maintained the mitochondrial function, ROS and MDA levels, and SOD activity.
Inhibited neural cell apoptosis in hippocampus, enhanced the hippocampal BDNF pathway and synaptic structural complexity. |
| [References]
[1]. Sabbah HN et al. Chronic Therapy With Elamipretide (MTP-131), a Novel Mitochondria-Targeting Peptide, Improves Left Ventricular and Mitochondrial Function in Dogs With Advanced Heart Failure. Circ Heart Fail. 2016 Feb;9(2):e002206. |
|
|